Ensysce Biosciences Reaches 50% Enrollment Milestone in Phase 3 Trial of PF614.

Ensysce Biosciences has reached the 50% enrollment milestone in its Phase 3 trial of PF614, a next-generation opioid candidate designed to provide effective pain relief while reducing risks associated with abuse. The trial is evaluating PF614 in patients experiencing moderate to severe pain following abdominoplasty surgery. Ensysce is a clinical-stage pharmaceutical company focused on developing novel pain treatments with built-in abuse and overdose protection.